Literature DB >> 28422316

Regulatory T cells: tolerance induction in solid organ transplantation.

T Vaikunthanathan1, N Safinia1, D Boardman1, R I Lechler1, G Lombardi1.   

Abstract

The concept of regulatory T cell (Treg ) therapy in transplantation is now a reality. Significant advances in science and technology have enabled us to isolate human Tregs , expand them to clinically relevant numbers and infuse them into human transplant recipients. With several Phase I/II trials under way investigating Treg safety and efficacy it is now more crucial than ever to understand their complex biology. However, our journey is by no means complete; results from these trials will undoubtedly provoke both further knowledge and enquiry which, alongside evolving science, will continue to drive the optimization of Treg therapy in the pursuit of transplantation tolerance. In this review we will summarize current knowledge of Treg biology, explore novel technologies in the setting of Treg immunotherapy and address key prerequisites surrounding the clinical application of Tregs in transplantation.
© 2017 British Society for Immunology.

Entities:  

Keywords:  cell therapy; clinical trials; immunotherapy; regulatory T cells; tolerance; transplantation

Mesh：

Substances：

Year:  2017        PMID： 28422316      PMCID： PMC5508315          DOI： 10.1111/cei.12978

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  133 in total

1.  Expression of dual TCR on DO11.10 T cells allows for ovalbumin-induced oral tolerance to prevent T cell-mediated colitis directed against unrelated enteric bacterial antigens.

Authors:  Pengfei Zhou; Rajka Borojevic; Cathy Streutker; Denis Snider; Hong Liang; Kenneth Croitoru
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

2.  In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance.

Authors:  Dela Golshayan; Shuiping Jiang; Julia Tsang; Marina I Garin; Christian Mottet; Robert I Lechler
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

Review 3.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

4.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

Review 5.  Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?

Authors:  Jochen Huehn; Julia K Polansky; Alf Hamann
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

6.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

7.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.

Authors:  Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

8.  CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Authors:  Moa Fransson; Elena Piras; Joachim Burman; Berith Nilsson; Magnus Essand; Binfeng Lu; Robert A Harris; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  J Neuroinflammation       Date:  2012-05-30       Impact factor: 8.322

9.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

10.  Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.

Authors:  A L Putnam; N Safinia; A Medvec; M Laszkowska; M Wray; M A Mintz; E Trotta; G L Szot; W Liu; A Lares; K Lee; A Laing; R I Lechler; J L Riley; J A Bluestone; G Lombardi; Q Tang
Journal:  Am J Transplant       Date:  2013-09-18       Impact factor: 8.086
View more
  23 in total

Review 1.  Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.

Authors:  Antoine Sicard; Megan K Levings; David W Scott
Journal:  Am J Transplant       Date:  2018-04-21       Impact factor: 8.086

2.  Immune tolerance in transplantation.

Authors:  Thomas Wekerle
Journal:  Clin Exp Immunol       Date:  2017-08       Impact factor: 4.330

3.  Treg-mediated prolonged survival of skin allografts without immunosuppression.

Authors:  Nina Pilat; Mario Wiletel; Anna M Weijler; Romy Steiner; Benedikt Mahr; Joanna Warren; Theresa M Corpuz; Thomas Wekerle; Kylie E Webster; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-13       Impact factor: 11.205

Review 4.  Regulatory T Cells and Kidney Transplantation.

Authors:  Paloma Leticia Martin-Moreno; Sudipta Tripathi; Anil Chandraker
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-22       Impact factor: 8.237

5.  Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation.

Authors:  Emma Proics; Marion David; Majid Mojibian; Madeline Speck; Nadia Lounnas-Mourey; Adeline Govehovitch; Wissam Baghdadi; Justine Desnouveaux; Hervé Bastian; Laura Freschi; Geoffrey Privat; Cédric Pouzet; Mauro Grossi; Pierre Heimendinger; Tobias Abel; David Fenard; Megan K Levings; François Meyer; Céline Dumont
Journal:  Gene Ther       Date:  2022-08-05       Impact factor: 4.184

6.  A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy.

Authors:  Esther Bernaldo-de-Quirós; Beatriz Cózar; Rocío López-Esteban; Maribel Clemente; Juan Miguel Gil-Jaurena; Carlos Pardo; Ana Pita; Ramón Pérez-Caballero; Manuela Camino; Nuria Gil; María Eugenia Fernández-Santos; Susana Suarez; Marjorie Pion; Marta Martínez-Bonet; Rafael Correa-Rocha
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

Review 7.  From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.

Authors:  Ayman F Refaie; Batoul L Elbassiouny; Malgorzata Kloc; Omaima M Sabek; Sherry M Khater; Amani M Ismail; Rania H Mohamed; Mohamed A Ghoneim
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

8.  In vivo Treg expansion under costimulation blockade targets early rejection and improves long-term outcome.

Authors:  Christoph Schwarz; Benedikt Mahr; Moritz Muckenhuber; Anna Marianne Weijler; Lukas Walter Unger; Nina Pilat; Michaela Latus; Heinz Regele; Thomas Wekerle
Journal:  Am J Transplant       Date:  2021-08-23       Impact factor: 9.369

Review 9.  Forkhead-Box-P3 Gene Transfer in Human CD4+ T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy.

Authors:  Laura Passerini; Rosa Bacchetta
Journal:  Front Immunol       Date:  2017-10-12       Impact factor: 7.561

Review 10.  Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.

Authors:  Priscila Ferreira Slepicka; Mahboubeh Yazdanifar; Alice Bertaina
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.